| Matthew Ray Whittaker, DO | |
|
4401 S Western Ave, Oklahoma City, OK 73109-3413 | |
| (405) 636-7195 | |
| (405) 979-8459 |
| Full Name | Matthew Ray Whittaker |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 5 Years |
| Location | 4401 S Western Ave, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043873706 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Faith Community Hospital | Jacksboro, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Concord Medical Group Of Texas Pllc | 7810117223 | 252 |
| Concord Medical Group Of Texas Pllc | 7810117223 | 252 |
| Concord Medical Group Pllc | 0446296818 | 158 |
News Archive
The Lupus Research Institute (LRI) today named 12 new grant recipients for 2009. The awards, totaling $3.6 million, recognize innovative work across a broad spectrum of lupus research. All were selected for their creativity, novelty, and potential to drive scientific discovery to ultimately prevent, treat, and cure the complex disease of systemic lupus.
Xiaoting Zhang, PhD, associate professor of cancer biology at the University of Cincinnati College of Medicine, received federal funding, an R01 grant from the National Cancer Institute, to study certain genetic material, known as small RNAs, in breast cancer metastasis (or spread).
Age-related Macular Degeneration (AMD), which affects more than 10 million older Americans, continues to be the leading cause of vision loss in the United States. The global cost of the disease according to a recent report by AMD Alliance International (AMDAI) is estimated at $343 billion, underscoring the need for swift actions to raise awareness of prevention and treatment options.
Tenofovir disoproxil fumarate monotherapy may be sufficient to maintain complete virological suppression in patients with chronic hepatitis B virus infection previously treated with TDF plus entecavir, suggests a review of patients.
Certara-, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer.
› Verified 2 days ago
| Entity Name | Emergency Staffing Solutions Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477590974 PECOS PAC ID: 9830001650 Enrollment ID: O20050207000313 |
News Archive
The Lupus Research Institute (LRI) today named 12 new grant recipients for 2009. The awards, totaling $3.6 million, recognize innovative work across a broad spectrum of lupus research. All were selected for their creativity, novelty, and potential to drive scientific discovery to ultimately prevent, treat, and cure the complex disease of systemic lupus.
Xiaoting Zhang, PhD, associate professor of cancer biology at the University of Cincinnati College of Medicine, received federal funding, an R01 grant from the National Cancer Institute, to study certain genetic material, known as small RNAs, in breast cancer metastasis (or spread).
Age-related Macular Degeneration (AMD), which affects more than 10 million older Americans, continues to be the leading cause of vision loss in the United States. The global cost of the disease according to a recent report by AMD Alliance International (AMDAI) is estimated at $343 billion, underscoring the need for swift actions to raise awareness of prevention and treatment options.
Tenofovir disoproxil fumarate monotherapy may be sufficient to maintain complete virological suppression in patients with chronic hepatitis B virus infection previously treated with TDF plus entecavir, suggests a review of patients.
Certara-, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer.
› Verified 2 days ago
| Entity Name | Ess Of Sallisaw, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215431069 PECOS PAC ID: 6002170578 Enrollment ID: O20180509000869 |
News Archive
The Lupus Research Institute (LRI) today named 12 new grant recipients for 2009. The awards, totaling $3.6 million, recognize innovative work across a broad spectrum of lupus research. All were selected for their creativity, novelty, and potential to drive scientific discovery to ultimately prevent, treat, and cure the complex disease of systemic lupus.
Xiaoting Zhang, PhD, associate professor of cancer biology at the University of Cincinnati College of Medicine, received federal funding, an R01 grant from the National Cancer Institute, to study certain genetic material, known as small RNAs, in breast cancer metastasis (or spread).
Age-related Macular Degeneration (AMD), which affects more than 10 million older Americans, continues to be the leading cause of vision loss in the United States. The global cost of the disease according to a recent report by AMD Alliance International (AMDAI) is estimated at $343 billion, underscoring the need for swift actions to raise awareness of prevention and treatment options.
Tenofovir disoproxil fumarate monotherapy may be sufficient to maintain complete virological suppression in patients with chronic hepatitis B virus infection previously treated with TDF plus entecavir, suggests a review of patients.
Certara-, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer.
› Verified 2 days ago
| Entity Name | Premier Physician Staffing 2 Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326509407 PECOS PAC ID: 3375886476 Enrollment ID: O20190513000686 |
News Archive
The Lupus Research Institute (LRI) today named 12 new grant recipients for 2009. The awards, totaling $3.6 million, recognize innovative work across a broad spectrum of lupus research. All were selected for their creativity, novelty, and potential to drive scientific discovery to ultimately prevent, treat, and cure the complex disease of systemic lupus.
Xiaoting Zhang, PhD, associate professor of cancer biology at the University of Cincinnati College of Medicine, received federal funding, an R01 grant from the National Cancer Institute, to study certain genetic material, known as small RNAs, in breast cancer metastasis (or spread).
Age-related Macular Degeneration (AMD), which affects more than 10 million older Americans, continues to be the leading cause of vision loss in the United States. The global cost of the disease according to a recent report by AMD Alliance International (AMDAI) is estimated at $343 billion, underscoring the need for swift actions to raise awareness of prevention and treatment options.
Tenofovir disoproxil fumarate monotherapy may be sufficient to maintain complete virological suppression in patients with chronic hepatitis B virus infection previously treated with TDF plus entecavir, suggests a review of patients.
Certara-, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer.
› Verified 2 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20210107000494 |
News Archive
The Lupus Research Institute (LRI) today named 12 new grant recipients for 2009. The awards, totaling $3.6 million, recognize innovative work across a broad spectrum of lupus research. All were selected for their creativity, novelty, and potential to drive scientific discovery to ultimately prevent, treat, and cure the complex disease of systemic lupus.
Xiaoting Zhang, PhD, associate professor of cancer biology at the University of Cincinnati College of Medicine, received federal funding, an R01 grant from the National Cancer Institute, to study certain genetic material, known as small RNAs, in breast cancer metastasis (or spread).
Age-related Macular Degeneration (AMD), which affects more than 10 million older Americans, continues to be the leading cause of vision loss in the United States. The global cost of the disease according to a recent report by AMD Alliance International (AMDAI) is estimated at $343 billion, underscoring the need for swift actions to raise awareness of prevention and treatment options.
Tenofovir disoproxil fumarate monotherapy may be sufficient to maintain complete virological suppression in patients with chronic hepatitis B virus infection previously treated with TDF plus entecavir, suggests a review of patients.
Certara-, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Ray Whittaker, DO 408 S Chestnut Ave, Broken Arrow, OK 74012-3407 Ph: (918) 706-1011 | Matthew Ray Whittaker, DO 4401 S Western Ave, Oklahoma City, OK 73109-3413 Ph: (405) 636-7195 |
News Archive
The Lupus Research Institute (LRI) today named 12 new grant recipients for 2009. The awards, totaling $3.6 million, recognize innovative work across a broad spectrum of lupus research. All were selected for their creativity, novelty, and potential to drive scientific discovery to ultimately prevent, treat, and cure the complex disease of systemic lupus.
Xiaoting Zhang, PhD, associate professor of cancer biology at the University of Cincinnati College of Medicine, received federal funding, an R01 grant from the National Cancer Institute, to study certain genetic material, known as small RNAs, in breast cancer metastasis (or spread).
Age-related Macular Degeneration (AMD), which affects more than 10 million older Americans, continues to be the leading cause of vision loss in the United States. The global cost of the disease according to a recent report by AMD Alliance International (AMDAI) is estimated at $343 billion, underscoring the need for swift actions to raise awareness of prevention and treatment options.
Tenofovir disoproxil fumarate monotherapy may be sufficient to maintain complete virological suppression in patients with chronic hepatitis B virus infection previously treated with TDF plus entecavir, suggests a review of patients.
Certara-, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer.
› Verified 2 days ago
Dr. Hunter Dale Cook, D.O Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4401 S Western Ave, Oklahoma City, OK 73109 Phone: 405-636-7709 | |
Alejandro Anzaldua, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 900 Ne 10th St, Fmc 2102, Oklahoma City, OK 73104 Phone: 405-271-2230 | |
Dr. Diana Dee Mills-maloney, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 10312 Creek Meadow Dr, Oklahoma City, OK 73151 Phone: 405-771-3577 | |
Dr. David Brennan, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4401 S Western Ave, Oklahoma City, OK 73109 Phone: 405-636-7000 | |
Aaron Daniel Jones, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4401 S Western Ave, Oklahoma City, OK 73109 Phone: 405-636-7000 | |
Dr. David M. Abercrombie, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1624 Grey Fox Run, Oklahoma City, OK 73131 Phone: 405-478-3969 Fax: 405-478-3815 | |
Dr. Amy L. Sparkman, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 940 Ne 13th St, Oklahoma City, OK 73104 Phone: 405-271-2429 |